Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus SOX as neoadjuvant therapy in locally advanced gastric adenocarcinoma (Phase II)
ChiCTR2500109535Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in gastric adenocarcinoma, sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: pathological complete response rate. Started Sep 2025; status: recruiting.
02
Drugs
sintilimab
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500109535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109535.